Combination of molecular-targeted drugs with endocrine therapy for hormone-resistant breast cancer

Overcoming resistance to endocrine therapy is the most intensive research area in estrogen receptor (ER)-positive breast cancer. A strategy to restore endocrine sensitivity using molecular-targeted drugs such as mammalian target of rapamycin inhibitor everolimus along with endocrine therapy has alre...

Full description

Saved in:
Bibliographic Details
Published in:International journal of clinical oncology 2015-04, Vol.20 (2), p.268-272
Main Authors: Saji, Shigehira, Kimura-Tsuchiya, Reiko
Format: Article
Language:English
Subjects:
Antineoplastic Agents, Hormonal - administration & dosage
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Breast cancer
Breast Neoplasms - drug therapy
Cancer Research
Cyclin-Dependent Kinase 4 - antagonists & inhibitors
Cyclin-Dependent Kinase 6 - antagonists & inhibitors
Drug Resistance, Neoplasm
Endocrine therapy
Female
Histone Deacetylase Inhibitors - administration & dosage
Humans
Medicine
Medicine & Public Health
Molecular Targeted Therapy
Oncology
Pharmacology
Protein Kinase Inhibitors - administration & dosage
Review Article
Signal Transduction - drug effects
Surgical Oncology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Overcoming resistance to endocrine therapy is the most intensive research area in estrogen receptor (ER)-positive breast cancer. A strategy to restore endocrine sensitivity using molecular-targeted drugs such as mammalian target of rapamycin inhibitor everolimus along with endocrine therapy has already been used as a treatment option after the progression of previous aromatase inhibitor therapy. Phase II/III clinical trials of several signal pathway inhibitors and cyclin-dependent kinase 4/6 inhibitors are underway. In addition, a randomized phase II trial of the histone deacetylase inhibitor entinostat showed interesting findings. In this review, we summarize the mechanistic principles of combination therapy of molecular-targeted drugs with endocrine therapy by using a hybrid car model.
ISSN:1341-9625
1437-7772
DOI:10.1007/s10147-015-0799-2